Drug-induced lupus erythematosus: Incidence, management and prevention

Drug Safety

Volumn 34, Issue 5, 2011, Pages 357-374

  Chang, Christopher ^a   Gershwin, M Eric ^b  

^a NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Autoimmune disorders; Chlorpromazine; Cytokines; Hydralazine; Minocycline; Procainamide; Quinidine; Systemic lupus erythematosus; Systemic lupus erythematosus; Tumour necrosis factor alpha inhibitors

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIFUNGAL AGENT; ANTIHISTAMINIC AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; ANTIMIGRAINE AGENT; ANTIPARASITIC AGENT; ANTIPARKINSON AGENT; ANTITHROMBOCYTIC AGENT; ANTITHYROID AGENT; AROMATASE INHIBITOR; CHELATING AGENT; ETANERCEPT; GONADORELIN AGONIST; HYDRALAZINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLIXIMAB; MINOCYCLINE; MONOCLONAL ANTIBODY; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PROCAINAMIDE; QUINIDINE; SULFADIAZINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNINDEXED DRUG; XANTHINE OXIDASE INHIBITOR;

ANTIBODY PRODUCTION; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CLINICAL FEATURE; DISEASE ASSOCIATION; DRUG INDUCED DISEASE; DRUG SAFETY; EARLY DIAGNOSIS; HUMAN; IMMUNOPATHOGENESIS; IMMUNOSTIMULATION; INCIDENCE; LUPUS LIKE SYNDROME; PATHOPHYSIOLOGY; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SKIN LUPUS ERYTHEMATOSUS;

ANIMALS; CYTOKINES; HUMANS; IMMUNOLOGIC FACTORS; LUPUS ERYTHEMATOSUS, CUTANEOUS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PHARMACEUTICAL PREPARATIONS; TUMOR NECROSIS FACTORS;

EID: 79955395000     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11588500-000000000-00000     Document Type: Review

References (95)

1. Borchers AT, Keen CL, Gershwin ME. Drug-induced lupus. Ann N Y Acad Sci 2007 Jun; 1108: 166-82 (Pubitemid 47528730)
2. Chang C, Gershwin ME. Drugs and autoimmunity: a contemporary review and mechanistic approach. J Autoimmun 2010 May; 34 (3): J266-75
3. Arnson Y, Shoenfeld Y, Amital H. Effects of tobacco smoke on immunity, inflammation and autoimmunity. J Autoimmun 2010 May; 34 (3): J258-65
4. Borchers AT, Naguwa SM, Shoenfeld Y, et al. The geoepidemiology of systemic lupus erythematosus. Autoimmun Rev 2010 Mar; 9 (5): A277-87
5. Chang C. The immune effects of naturally occurring and synthetic nanoparticles. J Autoimmun 2010 May; 34 (3): J234-46
6. Powell JJ, Faria N, Thomas-McKay E, et al. Origin and fate of dietary nanoparticles and microparticles in the gastrointestinal tract. J Autoimmun 2010 May; 34 (3): J226-33
7. Selmi C, Tsuneyama K. Nutrition, geoepidemiology, and autoimmunity. Autoimmun Rev 2010 Mar; 9 (5): A267-70
8. Tobon GJ, Youinou P, Saraux A. The environment, geoepidemiology, and autoimmune disease: rheumatoid arthritis. J Autoimmun 2010 Aug; 35 (1): 10-4
9. Tomer Y. Hepatitis C and interferon induced thyroiditis. J Autoimmun 2010 May; 34 (3): J322-6
10. Youinou P, Pers JO, Gershwin ME, et al. Geo-epidemiology and autoimmunity. J Autoimmun 2010 May; 34 (3): J163-7
11. Hoffman BJ. Sensitivity to sulfadiazine resembling acute disseminated lupus erythematosus. Arch Dermatol Syphilol 1945; 51: 190-2
12. Sanford HS, Michaelson AK, Halpern MM. Procainamide induced lupus erythematosus syndrome. Dis Chest 1967 Feb; 51 (2): 172-6
13. Reinhardt DJ, Waldron JM. Lupus erythematosus-like syndrome complicating hydralazine (apresoline) therapy. J Am Med Assoc 1954; 155: 1491-2
14. Yokoyama T, Usui T, Kiyama K, et al. Two cases of lateonset drug-induced lupus erythematosus caused by ticlopidine in elderlymen.Mod Rheumatol 2010Aug; 20 (4): 405-9
15. Reich A, Bialynicki-Birula R, Szepietowski JC. Druginduced subacute cutaneous lupus erythematosus resulting from ticlopidine. Int J Dermatol 2006 Sep; 45 (9): 1112-4 (Pubitemid 44317138)
16. Sontheimer RD, Henderson CL, Grau RH. Drug-induced subacute cutaneous lupus erythematosus: a paradigm for bedside-to-bench patient-oriented translational clinical investigation. Arch Dermatol Res 2009 Jan; 301 (1): 65-70
17. Bonsmann G, Schiller M, Luger TA, et al. Terbinafine-induced subacute cutaneous lupus erythematosus. J Am Acad Dermatol 2001 Jun; 44 (6): 925-31 (Pubitemid 32493441)
18. Srivastava M, Rencic A, Diglio G, et al. Drug-induced, Ro/SSA-positive cutaneous lupus erythematosus. Arch Dermatol 2003 Jan; 139 (1): 45-9 (Pubitemid 36091573)
19. Kluger N, Bessis D, Guillot B. Chronic cutaneous lupus flare induced by systemic 5-fluorouracil. J Dermatol Treatment 2006; 17: 51-3 (Pubitemid 43247309)
20. Rubin RL. Drug-induced lupus. Toxicology 2005 Apr 15; 209 (2): 135-47 (Pubitemid 40568641)
21. Ladd AT. Procainamide-induced lupus erythematosus. N Engl J Med 1962; 267: 1357-8
22. Mongey AB, Donovan-Brand R, Thomas TJ, et al. Serologic evaluation of patients receiving procainamide. Arthritis Rheum 1992; 35: 1108-9
23. Morrow JD, Schroeder HA, Perry Jr HM. Studies on the control of hypertension by hyphex: II. toxic reactions and side effects. Circulation 1953 Dec; 8 (6): 829-39
24. YokogawaN, Vivino FB. Hydralazine-induced autoimmune disease: comparison to idiopathic lupus and ANCA-positive vasculitic. Mod Rheumatol 2009; 19: 338-47
25. Bernstein RM, Egerton-Vernon J, Webster J. Hydrallazine induced cutaneous vasculitis. BMJ 1980; 280: 156-7
26. Yokogawa N, Vivino FB. Hydralazine-induced autoimmune disease: comparison to idiopathic lupus and ANCA-positive vasculitis. Mod Rheumatol 2009; 19 (3): 338-47
27. Mongey AB, Donovan-Brand R, Thomas TJ, et al. Serologic evaluation of patients receiving procainamide. Arthritis Rheum 1992 Feb; 35 (2): 219-23
28. Rubin RL, Bell SA, Burlingame RW. Autoantibodies associated with lupus induced by diverse drugs target a similar epitope in the (H2A-H2B)-DNA complex. J Clin Invest 1992 Jul; 90 (1): 165-73
29. Cohen MG, Kevat S, Prowse MV, et al. Two distinct quinidine- induced rheumatic syndromes. Ann Intern Med 1988 Mar; 108 (3): 369-71
30. Eichenfield AH. Minocycline and autoimmunity. Curr Opin Pediatr 1999 Oct; 11 (5): 447-56 (Pubitemid 29463067)
31. Matsuura T, Shimizu Y, Fujimoto H, et al. Minocycline induced lupus. Lancet 1992; 340: 1553
32. Schlienger RG, Bircher AJ,Meier CR. Minocycline-induced lupus: a systematic review. Dermatology 2000; 200 (3): 223-31 (Pubitemid 30265307)
33. El-Hallak M, Giani T, Yaniay BS, et al. Chronic minocycline- induced lupus autoimmunity in children. J Pediatr 2008; 153: 303-4
34. Lawson TM, AmosN, Bulgen D, et al. Minocycline-induced lupus: clinical features and response to rechallenge. Rheumatology (Oxford) 2001 Mar; 40 (3): 329-35
35. Dunphy J, Oliver M, Rands AL, et al. Antineutrophil cytoplasmic antibodies and HLA class II alleles in minocyclineinduced lupus-like syndrome. Br J Dermatol 2000 Mar; 142 (3): 461-7 (Pubitemid 30159068)
36. Walshe JM. Penicillamine and the SLE syndrome. J Rheumatol Suppl 1981; 7: 155-60 (Pubitemid 11108139)
37. Bray VJ, West SG, Schultz KT, et al. Antihistone antibody profile in sulfasalazine induced lupus. J Rheumatol 1994 Nov; 21 (11): 2157-8 (Pubitemid 24352369)
38. Gunnarsson I, Nordmark B, Hassan Bakri A, et al. Development of lupus-related side-effects in patients with early RA during sulphasalazine treatment-the role of IL-10 and HLA. Rheumatology (Oxford) 2000 Aug; 39 (8): 886-93 (Pubitemid 30649517)
39. Noel B. Lupus erythematosus and other autoimmune diseases related to statin therapy: a systematic review. J Eur Acad Dermatol Venereol 2007 Jan; 21 (1): 17-24 (Pubitemid 44942318)
40. Bonaci-Nikolic B, Nikolic MM, Andrejevic S, et al. Antineutrophil cytoplasmic antibody (ANCA)-associated autoimmune diseases induced by antithyroid drugs: comparison with idiopathic ANCA vasculitides. Arthritis Res Ther 2005; 7 (5): R1072-81
41. Metcalf RG, Kuna A, Maccarron D. Disseminated lupus erythematosus versus drug reaction: report of a case receiving chlorpromazine. J Maine Med Assoc 1959 Jul; 50 (7): 251-4
42. Canoso RT, de Oliveira RM. Chlorpromazine-induced anticardiolipin antibodies and lupus anticoagulant: absence of thrombosis. Am J Hematol 1988 Apr; 27 (4): 272-5
43. Canoso RT, Sise HS. Chlorpromazine-induced lupus anticoagulant and associated immunologic abnormalities. Am J Hematol 1982 Sep; 13 (2): 121-9 (Pubitemid 12009556)
44. Laroche M, Borg S, Lassoued S, et al. Joint pain with aromatase inhibitors: abnormal frequency of Sjogren's syndrome. J Rheumatol 2007 Nov; 34 (11): 2259-63 (Pubitemid 350076888)
45. Barendrecht MM, Tervaert JW, van Breda Vriesman PJ, et al. Susceptibility to cyclosporin A-induced autoimmunity: strain differences in relation to autoregulatory T cells. J Autoimmun 2002 Feb; 18 (1): 39-48 (Pubitemid 34252592)
46. Rao T, Richardson B. Environmentally induced autoimmune diseases: potential mechanisms. Environ Health Perspect 1999 Oct; 107 Suppl. 5: 737-42 (Pubitemid 29527778)
47. Molina V, Shoenfeld Y. Infection, vaccines and other environmental triggers of autoimmunity. Autoimmunity 2005 May; 38 (3): 235-45 (Pubitemid 40959897)
48. Abedi-Valugerdi M. Mercury and silver induce B cell activation and anti-nucleolar autoantibody production in outbred mouse stocks: are environmental factors more important than the susceptibility genes in connection with autoimmunity? Clin Exp Immunol 2009 Jan; 155 (1): 117-24
49. Rothschild B. Acrylamine-induced autoimmune phenomena. Clin Rheumatol 2010 Sep; 29 (9): 999-1005
50. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998 Sep; 41 (9): 1552-63 (Pubitemid 28459913)
51. Elliott MJ, Maini RN, Feldmann M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 1993 Dec; 36 (12): 1681-90 (Pubitemid 23360007)
52. Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994 Oct 22; 344 (8930): 1105-10 (Pubitemid 24317629)
53. Charles PJ, Smeenk RJ, De Jong J, et al. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 2000 Nov; 43 (11): 2383-90
54. Williams EL, Gadola S, Edwards CJ. Anti-TNF-induced lupus. Rheumatology (Oxford) 2009 Jul; 48 (7): 716-20
55. De Rycke L, Kruithof E, Van Damme N, et al. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. Arthritis Rheum 2003 Apr; 48 (4): 1015-23 (Pubitemid 36418243)
56. Ramos-CasalsM, Brito-Zeron P,Munoz S, et al.Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 2007 Jul; 86 (4): 242-51 (Pubitemid 47067483)
57. Vermeire S, Noman M, Van Assche G, et al. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. Gastroenterology 2003 Jul; 125 (1): 32-9 (Pubitemid 36799104)
58. Costa MF, Said NR, Zimmermann B. Drug-induced lupus due to anti-tumor necrosis factor alpha agents. Semin Arthritis Rheum 2008 Jun; 37 (6): 381-7 (Pubitemid 351734520)
59. De Bandt M, Sibilia J, Le Loet X, et al. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther 2005; 7 (3): R545-51
60. Elkayam O, Burke M, Vardinon N, et al. Autoantibodies profile of rheumatoid arthritis patients during treatment with infliximab. Autoimmunity 2005 Mar; 38 (2): 155-60 (Pubitemid 40872740)
61. Jonsdottir T, Forslid J, van Vollenhoven A, et al. Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies. Ann Rheum Dis 2004 Sep; 63 (9): 1075-8 (Pubitemid 39120357)
62. De Rycke L, Baeten D, Kruithof E, et al. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis. Arthritis Rheum 2005 Jul; 52 (7): 2192-201 (Pubitemid 40994342)
63. Eriksson C, Engstrand S, Sundqvist KG, et al. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha. Ann Rheum Dis 2005 Mar; 64 (3): 403-7 (Pubitemid 40283050)
64. Stokes MB, Foster K, Markowitz GS, et al. Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis. Nephrol Dial Transplant 2005 Jul; 20 (7): 1400-6 (Pubitemid 41430613)
65. Mohan N, Edwards ET, Cupps TR, et al. Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents. J Rheumatol 2004 Oct; 31 (10): 1955-8 (Pubitemid 39336719)
66. Mor A, Bingham 3rd C, Barisoni L, et al. Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept. J Rheumatol 2005 Apr; 32 (4): 740-3 (Pubitemid 40524710)
67. De BandtM. Lessons for lupus from tumour necrosis factor blockade. Lupus 2006; 15 (11): 762-7
68. Ronnblom LE, Alm GV, Oberg KE. Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Ann Intern Med 1991 Aug 1; 115 (3): 178-83
69. Gogas H, Ioannovich J, Dafni U, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006 Feb 16; 354 (7): 709-18 (Pubitemid 43247141)
70. Atkins MB, Mier JW, Parkinson DR, et al. Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells. N Engl J Med 1988 Jun 16; 318 (24): 1557-63
71. Massarotti EM, Liu NY, Mier J, et al. Chronic inflammatory arthritis after treatment with high-dose interleukin-2 for malignancy. Am J Med 1992 Jun; 92 (6): 693-7
72. Pichler WJ. Pharmacological interaction of drugs with antigen- specific immune receptors: the p-i concept. Curr Opin Allergy Clin Immunol 2002 Aug; 2 (4): 301-5 (Pubitemid 36869638)
73. Uetrecht JP. Current trends in drug-induced autoimmunity. Toxicology 1997 Apr 11; 119 (1): 37-43 (Pubitemid 27144255)
74. Kretz-Rommel A, Duncan SR, Rubin RL. Autoimmunity caused by disruption of central T cell tolerance: a murine model of drug-induced lupus. J Clin Invest 1997 Apr 15; 99 (8): 1888-96 (Pubitemid 27175936)
75. Rubin RL, Kretz-Rommel A. Initiation of autoimmunity by a reactive metabolite of a lupus-inducing drug in the thymus. Environ Health Perspect 1999 Oct; 107 Suppl. 5: 803-6 (Pubitemid 29527786)
76. Kretz-Rommel A, Rubin RL. Disruption of positive selection of thymocytes causes autoimmunity. Nat Med 2000 Mar; 6 (3): 298-305 (Pubitemid 30148622)
77. Ablin J, Verbovetski I, Trahtemberg U, et al. Quinidine and procainamide inhibit murine macrophage uptake of apoptotic and necrotic cells: a novel contributing mechanism of drug-induced-lupus. Apoptosis 2005 Oct; 10 (5): 1009-18 (Pubitemid 41285579)
78. Hieronymus T, Grotsch P, Blank N, et al. Chlorpromazine induces apoptosis in activated human lymphoblasts: a mechanism supporting the induction of drug-induced lupus erythematosus? Arthritis Rheum 2000 Sep; 43 (9): 1994-2004
79. Balada E, Ordi-Ros J, Vilardell-Tarres M. DNA methylation and systemic lupus erythematosus. Ann N Y Acad Sci 2007 Jun; 1108: 127-36 (Pubitemid 47528726)
80. Deng C, Lu Q, Zhang Z, et al. Hydralazine may induce autoimmunity by inhibiting extracellular signal-regulated kinase pathway signaling. Arthritis Rheum 2003 Mar; 48 (3): 746-56 (Pubitemid 36302012)
81. Gorelik G, Fang JY, Wu A, et al. Impaired T cell protein kinase C delta activation decreases ERK pathway signaling in idiopathic and hydralazine-induced lupus. J Immunol 2007 Oct 15; 179 (8): 5553-63
82. Lu Q, Kaplan M, Ray D, et al. Demethylation of ITGAL (CD11a) regulatory sequences in systemic lupus erythematosus. Arthritis Rheum 2002 May; 46 (5): 1282-91 (Pubitemid 34525836)
83. Yung R, Powers D, Johnson K, et al. Mechanisms of druginduced lupus: II. T cells overexpressing lymphocyte function- associated antigen 1 become autoreactive and cause a lupuslike disease in syngeneic mice. J Clin Invest 1996 Jun 15; 97 (12): 2866-71 (Pubitemid 26197100)
84. Oelke K, Richardson B. Decreased T cell ERK pathway signaling may contribute to the development of lupus through effects on DNA methylation and gene expression. Int Rev Immunol 2004 May-Aug; 23 (3-4): 315-31 (Pubitemid 38812233)
85. Zhou Y, Lu Q. DNA methylation in T cells from idiopathic lupus and drug-induced lupus patients. Autoimmun Rev 2008 May; 7 (5): 376-83
86. Lu Q, Wu A, Richardson BC. Demethylation of the same promoter sequence increases CD70 expression in lupus T cells and T cells treated with lupus-inducing drugs. J Immunol 2005 May 15; 174 (10): 6212-9 (Pubitemid 40663812)
87. Mevorach D. Systemic lupus erythematosus and apoptosis: a question of balance. Clin Rev Allergy Immunol 2003 Aug; 25 (1): 49-60
88. Baima B, Sticherling M. Apoptosis in different cutaneous manifestations of lupus erythematosus. Br JDermatol 2001 May; 144 (5): 958-66
89. Blanco-Colio LM, Villa A, Ortego M, et al. 3-Hydroxy- 3-methyl-glutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation. Atherosclerosis 2002 Mar; 161 (1): 17-26 (Pubitemid 34214817)
90. Hakamada-Taguchi R, Uehara Y, Kuribayashi K, et al. Inhibition of hydroxymethylglutaryl-coenzyme a reductase reduces Th1 development and promotes Th2 development. Circ Res 2003 Nov 14; 93 (10): 948-56 (Pubitemid 37441285)
91. Youssef S, Stuve O, Patarroyo JC, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002 Nov 7; 420 (6911): 78-84 (Pubitemid 35291443)
92. Li J, Uetrecht JP. D-penicillamine-induced autoimmunity: relationship to macrophage activation. Chem Res Toxicol 2009 Sep; 22 (9): 1526-33
93. Damoiseaux JG, Beijleveld LJ, van Breda Vriesman PJ. Multiple effects of cyclosporin A on the thymus in relation to T-cell development and autoimmunity. Clin Immunol Immunopathol 1997 Mar; 82 (3): 197-202 (Pubitemid 27128304)
94. Ferraccioli G, Mecchia F, Di Poi E, et al. Anticardiolipin antibodies in rheumatoid patients treated with etanercept or conventional combination therapy: direct and indirect evidence for a possible association with infections. Ann Rheum Dis 2002 Apr; 61 (4): 358-61 (Pubitemid 34257750)
95. Wiik A. Drug-induced vasculitis. Curr Opin Rheumatol 2008 Jan; 20 (1): 35-9 (Pubitemid 351339430)